@article{f48ead56f497451c839e85a3f8e4582c,
title = "A novel approach to studying early knee osteoarthritis illustrates that bilateral medial tibiofemoral osteoarthritis is a heritable phenotype: an offspring study",
abstract = "To assess the potential of studying offspring of people with and without knee osteoarthritis to understand the risk factors and heritability for knee osteoarthritis. We selected two groups of Osteoarthritis Initiative (OAI) participants from one clinical site: (1) participants with bilateral radiographic medial tibiofemoral osteoarthritis and (2) those without tibiofemoral osteoarthritis. We then invited biological offspring ≥ 18 years old to complete an online survey that inquired about osteoarthritis risk factors and symptoms. Among the survey respondents, we recruited ten offspring of members from each group for a clinic visit with bilateral knee posterior-anterior radiographs and magnetic resonance imaging of the right knee. We established contact with 269/413 (65%) eligible OAI participants. Most (227/269, 84%) had ≥ 1 eligible biological offspring, and 213 (94%) were willing to share information about the new family study with their offspring. Our survey was completed by 188 offspring from 110 OAI participants: mean age of 43.0 (10.4) years, mean body mass index of 23.7 (5.9) kg/m2, 65% female. Offspring obesity (OR = 2.7, 95% CI 1.0–7.3), hypertension (OR = 3.7, 95% CI 1.2–11.3), and Heberden{\textquoteright}s nodes (OR = 3.6, 95% CI 1.0–13.2) were associated with parental osteoarthritis status; however, adjusted models were not statistically significant. Radiographic tibiofemoral osteoarthritis (16/18 knees vs. 2/20 knees) and meniscal abnormalities (7/9 vs. 2/10 index knees) were more common among offspring with parental osteoarthritis status than not. We established the potential of a novel offspring study design within the OAI, and our results are consistent with bilateral radiographic medial tibiofemoral osteoarthritis being a heritable phenotype of osteoarthritis.",
keywords = "Heritability, Knee, Offspring, Osteoarthritis",
author = "Lo, {Grace H.} and Richard, {Michael J.} and Cauley, {Jane A.} and Driban, {Jeffrey B.} and Michael Strayhorn and James MacKay and Harkey, {Matthew S.} and McAlindon, {Timothy E.} and Mary Jansen and Stephanie Green and White, {Donna L.} and Kwoh, {C. Kent}",
note = "Funding Information: This study is supported by R03AR069323, an NIH/NIAMS funded award, providing support for design and conduct of the study, analysis, and interpretation of the data and preparation and review of this work. This work is supported in part with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX. The Osteoarthritis Initiative is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Osteoarthritis Initiative is managed by the Foundation for the National Institutes of Health. MSH was supported by the National Institutes of Health (grant no. 5 TL1 TR 1454-3). We would like to thank Michael J. Hannon MA for his assistance in aspects of study design for this study. Funding Information: This study is supported by R03AR069323, an NIH/NIAMS funded award, providing support for design and conduct of the study, analysis, and interpretation of the data and preparation and review of this work. This work is supported in part with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX. The Osteoarthritis Initiative is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the Osteoarthritis Initiative Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Osteoarthritis Initiative is managed by the Foundation for the National Institutes of Health. MSH was supported by the National Institutes of Health (grant no. 5 TL1 TR 1454-3). We would like to thank Michael J. Hannon MA for his assistance in aspects of study design for this study. Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",
year = "2022",
month = jun,
doi = "10.1007/s00296-022-05116-1",
language = "English (US)",
volume = "42",
pages = "1063--1072",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "6",
}